STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate
of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast
cancer